2.3. The Addition of EB1089 to the Combination of Lapatinib and Antiestrogens Differentially Regulates ERα Protein Expression in HER2-Positive Breast Cancer Cells Depending on Cell Hormone Receptor Status. Here, ERBB2 is linked to breast cancer.